Title: Remdesivir in adults with severe COVID-19
Description: Remdesivir has an inhibitory effect on SARS-CoV-2 in the lab and in animals. This randomised, double-blind, placebo-controlled, multicentre clinical trial investigated Remdesivir’s effectiveness in eligible patients.
Description: This study sought to investigate the relationship between underlying cardiovascular disease and COVID-19 outcomes, and to evaluate the link between cardiovascular drug therapy and mortality in this illness.
Title: COVID-19, superinfections and antimicrobial development: What can we expect?
Description: The authors reviewed published data on bacterial and fungal infections among COVID-19 patients, and offer perspectives on what to expect with superinfections, antimicrobial resistance and antimicrobial development.
Title: Children and young people who are immunocompromised
Description: The guideline covers children and young people (aged 17 and under). It may also be relevant for new-born babies under 72 hours, and 18 to 24 year olds using healthcare services.
Title: Antibiotics for pneumonia in adults in hospital
Description: The purpose of this guideline is to ensure the best antibiotic management of suspected or confirmed bacterial pneumonia in adults in hospital during the COVID-19 pandemic.
Title: A third of COVID-19 patients admitted to UK hospitals die
Description: The author comments on a study which tracked the outcomes of 16,749 patients—from data gathered from 166 hospitals in England, Scotland, and Wales between 6 February and 18 April.
Title: COVID-19 is no worse in immunocompromised children, says NICE
Description: The author summarises the guideline above - highlighting areas of significance.
For additional support with accessing the publications above, visit www.wkp.nhs.uk
No comments:
Post a Comment